Genetic Characterization of blaNDM-1-Carrying Citrobacter portucalensis Sequence Type 328 and Citrobacter freundii Sequence Type 98

Wang, Lijun; Li, Ziyao; Xiao, Nan; Tang, Jie; He, Ya‐Ling; Guo, Jun; Zhao, Xiuying

doi:10.2147/idr.s361761

Cited by 2 publications

(1 citation statement)

References 31 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the misidentification of C. portucalensis as C. freundii has led to an underestimation of its prevalence in clinical settings. 7,26 In this study, L2724hy C. portucalensis was initially misidentified as C. freundii using MALDI-TOF/MS, and was later identified as C. portucalensis by a combination of 16s rRNA sequencing and ANI analysis. Thus, it is essential to enhance the whole-genome sequencing of less common strains.…”

Section: Discussionmentioning

confidence: 97%

Emergence of an Extensive Drug Resistant Citrobacter portucalensis Clinical Strain Harboring blaSFO-1, blaKPC-2, and blaNDM-1

Guo,

Zhao,

Yang

et al. 2024

IDR

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 97%

Emergence of an Extensive Drug Resistant Citrobacter portucalensis Clinical Strain Harboring blaSFO-1, blaKPC-2, and blaNDM-1

Guo,

Zhao,

Yang

et al. 2024

IDR

View full text Add to dashboard Cite

Microbial and Metabolic Gut Profiling across Seven Malignancies Identifies Fecal Faecalibacillus intestinalis and Formic Acid as Commonly Altered in Cancer Patients

Kulecka,

Czarnowski,

Bałabas

et al. 2024

IJMS

View full text Add to dashboard Cite

The key association between gut dysbiosis and cancer is already known. Here, we used whole-genome shotgun sequencing (WGS) and gas chromatography/mass spectrometry (GC/MS) to conduct metagenomic and metabolomic analyses to identify common and distinct taxonomic configurations among 40, 45, 71, 34, 50, 60, and 40 patients with colorectal cancer, stomach cancer, breast cancer, lung cancer, melanoma, lymphoid neoplasms and acute myeloid leukemia (AML), respectively, and compared the data with those from sex- and age-matched healthy controls (HC). α-diversity differed only between the lymphoid neoplasm and AML groups and their respective HC, while β-diversity differed between all groups and their HC. Of 203 unique species, 179 and 24 were under- and over-represented, respectively, in the case groups compared with HC. Of these, Faecalibacillus intestinalis was under-represented in each of the seven groups studied, Anaerostipes hadrus was under-represented in all but the stomach cancer group, and 22 species were under-represented in the remaining five case groups. There was a marked reduction in the gut microbiome cancer index in all case groups except the AML group. Of the short-chain fatty acids and amino acids tested, the relative concentration of formic acid was significantly higher in each of the case groups than in HC, and the abundance of seven species of Faecalibacterium correlated negatively with most amino acids and formic acid, and positively with the levels of acetic, propanoic, and butanoic acid. We found more differences than similarities between the studied malignancy groups, with large variations in diversity, taxonomic/metabolomic profiles, and functional assignments. While the results obtained may demonstrate trends rather than objective differences that correlate with different types of malignancy, the newly developed gut microbiota cancer index did distinguish most of the cancer cases from HC. We believe that these data are a promising step forward in the search for new diagnostic and predictive tests to assess intestinal dysbiosis among cancer patients.

show abstract

Genetic Characterization of blaNDM-1-Carrying Citrobacter portucalensis Sequence Type 328 and Citrobacter freundii Sequence Type 98

Cited by 2 publications

References 31 publications

Emergence of an Extensive Drug Resistant Citrobacter portucalensis Clinical Strain Harboring blaSFO-1, blaKPC-2, and blaNDM-1

Emergence of an Extensive Drug Resistant Citrobacter portucalensis Clinical Strain Harboring blaSFO-1, blaKPC-2, and blaNDM-1

Microbial and Metabolic Gut Profiling across Seven Malignancies Identifies Fecal Faecalibacillus intestinalis and Formic Acid as Commonly Altered in Cancer Patients

Contact Info

Product

Resources

About